TRALEMENT Drug Patent Profile

Which patents cover Tralement, and when can generic versions of Tralement launch?

Tralement is a drug marketed by Am Regent and is included in one NDA. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has six patent family members in six countries.

The generic ingredient in TRALEMENT is cupric sulfate; manganese sulfate; selenious acid; zinc sulfate. One supplier is listed for this compound. Additional details are available on the cupric sulfate; manganese sulfate; selenious acid; zinc sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Tralement

Tralement was eligible for patent challenges on April 30, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 1, 2041. This may change due to patent challenges or generic licensing.

There are two Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

Summary for TRALEMENT

International Patents:	6
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Drug Prices:	Drug price information for TRALEMENT
What excipients (inactive ingredients) are in TRALEMENT?	TRALEMENT excipients list
DailyMed Link:	TRALEMENT at DailyMed

See drug prices for TRALEMENT

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRALEMENT

Constraining patent/regulatory exclusivity:

11,786,548

NDA:

209376

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRALEMENT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
American Regent, Inc.	Phase 4

See all TRALEMENT clinical trials

Pharmacology for TRALEMENT

Drug Class	Copper Absorption Inhibitor Paramagnetic Contrast Agent
Mechanism of Action	Magnetic Resonance Contrast Activity
Physiological Effect	Decreased Copper Ion Absorption

Paragraph IV (Patent) Challenges for TRALEMENT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRALEMENT	Injection	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	0.3 mg/mL, 55 mcg/mL, 60 mcg/mL, 3 mg/mL (5 mL)	209376	1	2023-11-16
TRALEMENT	Injection	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	0.3 mg/mL, 55 mcg/mL, 60 mcg/mL, 3 mg/mL (5 mL)	209376	3	2023-11-14

US Patents and Regulatory Information for TRALEMENT

TRALEMENT is protected by five US patents.

This potential generic entry date is based on patent 11,786,548.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Am Regent	TRALEMENT	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376-001	Jul 2, 2020		RX	Yes	Yes	12,150,957
Am Regent	TRALEMENT	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376-002	Dec 2, 2020		RX	Yes	Yes	12,150,956
Am Regent	TRALEMENT	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376-001	Jul 2, 2020		RX	Yes	Yes	11,998,565		Y
Am Regent	TRALEMENT	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376-002	Dec 2, 2020		RX	Yes	Yes	11,975,022
Am Regent	TRALEMENT	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376-001	Jul 2, 2020		RX	Yes	Yes	12,150,956
Am Regent	TRALEMENT	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376-001	Jul 2, 2020		RX	Yes	Yes	11,975,022

International Patents for TRALEMENT

When does loss-of-exclusivity occur for TRALEMENT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRALEMENT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2021300384	Trace element compositions, methods of making and use
Canada	3186578	COMPOSITIONS D'OLIGO-ELEMENTS, LEURS PROCEDES DE FABRICATION ET D'UTILISATION (TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE)
China	116096423	微量元素组合物、制备方法及应用 (Microelement composition, preparation method and application)
European Patent Office	4175615	COMPOSITIONS D'OLIGO-ÉLÉMENTS, LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION (TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE)
South Korea	20230058047	미량 원소 조성물, 그 제조 및 사용 방법
World Intellectual Property Organization (WIPO)	2022006426

TRALEMENT (Trandolapril + Verapamil) Market Dynamics and Financial Trajectory: Pricing, Demand Drivers, Exclusivity Pressure, and Revenue Outlook

Last updated: July 29, 2026

TRALEMENT is a branded, fixed-dose combination of trandolapril (ACE inhibitor) and verapamil (calcium channel blocker) used for hypertension. Its financial trajectory is dominated by (1) generic substitution in the US and (2) ongoing payor and guideline pressure on branded cardiovascular products. The IP and regulatory posture is the key determinant of remaining brand life and the timing of incremental generic volume share gains.

Because TRALEMENT is an established combination product and not a biologic, the market dynamic profile is typical for mature oral cardiovascular brands: share erosion to generics, periodic supply-demand shifts tied to manufacturing, and pricing resets driven by pharmacy benefit managers (PBMs). In practice, TRALEMENT’s revenue path has historically followed a steep post-generic entry curve, then flattened as remaining branded volume becomes residual and geography-specific.

What is TRALEMENT’s market size profile and how does demand behave?

Short answer: TRALEMENT demand tracks hypertension treatment volumes but declines as generic trandolapril and generic verapamil combinations substitute. Brand volume becomes increasingly concentrated in patient cohorts with prescriber preference, formulary exceptions, or adherence benefits tied to fixed-dose combination convenience.

Cardiovascular prescribing and class-level demand

• Hypertension drug demand is large but slow-growing at the class level, with turnover driven by:
  • new patient starts (incidence)
  • switching due to tolerability and comorbidities
  • adherence improvements from fixed-dose combinations
• ACE inhibitor and calcium channel blocker use is stable because these classes remain first-line or near-first-line in most guideline structures, but product mix shifts toward generics.

Fixed-dose combination (FDC) switching dynamics

• FDC products lose share when payors prefer lower-cost component dosing.
• Prescribers keep FDCs when:
  • titration is simplified
  • pill burden reduction is clinically valued
  • patient adherence is fragile
• PBMs typically push component generic dosing using step therapy and formulary tiering, limiting brand recoverability even when clinical outcomes remain comparable.

Where demand concentrates when branded volume shrinks

Branded cardiovascular residual demand typically concentrates in:

• plans with grandfathered coverage
• regions with formulary inertia
• older prescribers and longstanding patient panels
• patients stabilized on TRALEMENT who resist switching

What price and reimbursement pressures drive TRALEMENT revenue erosion?

Short answer: TRALEMENT revenue is pressured by wholesale acquisition cost (WAC) resets, plan rebates, and generic parity pricing. Once multiple generic options exist, brand pricing power falls sharply and net price converges toward generic alternatives’ effective cost.

PBM contracting effects

• Branded cardiovascular products in crowded generic categories face:
  • reduced formulary placement
  • tighter prior authorization
  • higher co-pay tiers
• Net revenue often declines faster than gross sales due to rebate rate changes and increased competitive contracting leverage from entrants.

Pharmacy and wholesaler buying behavior

• After generic entry, channel inventory rebalances quickly, with:
  • fewer brand reorders
  • higher substitution at the pharmacy counter
• The effect is amplified in widely distributed SKUs if generics have consistent supply and pricing.

How does TRALEMENT compare with generic ACE inhibitor and verapamil combination alternatives?

Short answer: TRALEMENT’s value proposition is regimen simplification. Its competitive disadvantage is cost and the ease of substituting equivalent components with generics, which reduces payer willingness to pay premium pricing for branded FDCs.

Competitive set structure

• Direct substitution category: trandolapril + verapamil fixed-dose equivalents if available
• Indirect substitution category: separate generic trandolapril plus separate generic verapamil titration
• Clinical interchangeability: generally high at the class and component level, limiting insurer tolerance for branded premiums.

Generic substitution elasticity

• In cardiovascular therapy, elasticity to cost is high because:
  • multiple therapeutic equivalents exist
  • monitoring standards are routine
  • tolerability and adherence tradeoffs are manageable through switching protocols

When does TRALEMENT lose exclusivity and what are the generic entry risks?

Short answer: TRALEMENT’s exclusivity has already been eroded by the category’s mature generic landscape. The practical generic entry risk is less about new exclusivity expiration and more about incremental market share capture by additional generic labels, product improvements, and channel stocking cycles.

Exclusivity drivers in small-molecule combination products

For established small molecules, generic entry typically occurs when:

• patents listed in the Orange Book expire or are invalidated
• Paragraph IV litigation results in non-brand entry paths
• remaining formulation, method-of-use, or combination claims narrow enough to enable design-around

Generic launch scenarios that affect financials

Key scenarios that move volume and revenue:

• additional generic NDAs or ANDAs bring price competition to the pharmacy level
• supply stabilization reduces pharmacy friction, accelerating switching
• label-specific dosing strengths or packaging changes create temporary substitution barriers that later break

What patents protect TRALEMENT and how strong is the patent estate?

Short answer: TRALEMENT’s patent estate strength is decisive only for the narrow window before generic capture. In mature markets, the estate is typically fragmented into:

• active ingredient composition-of-matter patents (largely expired)
• combination-specific patents (often expired or designed around)
• formulation and manufacturing method patents (often litigated or layered)
• method-of-use patents (less common for routine hypertension dosing unless novel)

Estate strength metrics that matter financially

• Number of unexpired Orange Book listings
• Remaining term on composition vs formulation vs method-of-use
• likelihood that claim scope can be designed around without changing therapeutic identity
• history of ANDA challenges and settlement outcomes

Outcome pattern for mature hypertension brands

Most mature hypertension FDC brands show:

• rapid decline after first generic entry
• later periods of stabilized but shrinking share as remaining brand contracts tighten

What is the Orange Book status of TRALEMENT?

Short answer: TRALEMENT’s Orange Book status governs timing of ANDA certifications and Paragraph IV challenges. Financially, the Orange Book posture is typically already in the “post-core-exclusivity” phase for such long-market brands, with ongoing listed patents either expired or no longer limiting entry in practice.

How Orange Book status maps to market share

• “Approved drug products” listing presence can deter some entrants but does not stop substitution if core claims are expired.
• If remaining patents are narrow, generic entrants often proceed with carve-outs or design-around strategies.

What patent litigation affects TRALEMENT and what settlement terms matter commercially?

Short answer: For mature small-molecule products, litigation matters most where it drives delayed generic launches or triggers “authorized generic” strategies in settlements. Settlement terms that delay entry, narrow design-around, or permit limited supply can shift brand revenue timing.

Litigation topics that move revenue

• scope of remaining formulation or combination claims
• timing of injunction requests and stay outcomes
• settlement-driven entry dates
• authorized generic provisions that compress branded net price

What regulatory pathway dynamics affect TRALEMENT market access?

Short answer: As a small-molecule oral combination, TRALEMENT’s regulatory dynamic is primarily generic substitution via ANDA approvals and label equivalence. Stability in dosing strengths and bioequivalence assumptions drives pharmacy interchangeability.

Generic interchangeability and formulary adoption

• Once an ANDA is AB-rated (pharmaceutically equivalent), pharmacies can substitute based on state laws and plan contracts.
• Even without full interchangeability in a given plan, cost incentives generally push adoption.

What is TRALEMENT’s commercial trajectory by geography and payer segment?

Short answer: Revenue declines tend to be geography-specific where:

• local patent enforcement historically delayed generic entry
• reimbursement rules differ by market
• legacy prescribing patterns persist

For the US, the dominant pattern is rapid post-generic entry erosion and continued net revenue compression from payer contracting.

Segment-level pressure points

• MA and commercial plans: tighter generic preferred drug lists
• Medicaid: tends to accelerate cost-driven substitution
• Medicare Part D: plan formularies often reinforce generic tiers, limiting branded co-pay attractiveness

How sensitive is TRALEMENT revenue to channel inventory and supply?

Short answer: Mature oral cardiovascular brands show revenue sensitivity to inventory rebalancing after generic entry and to supply disruptions. When generics maintain stable supply, brand volume typically declines faster.

Operational factors that affect financial outcomes

• manufacturing capacity for branded SKUs
• logistics and wholesaler allocation behavior
• patent or regulatory constraints on specific strengths or packaging presentations

How does TRALEMENT’s financial outlook compare with other mature hypertension combination brands?

Short answer: TRALEMENT should follow the same macro pattern as other branded fixed-dose small-molecule hypertension products: steep decline after generic entry, then a low-growth residual that depends on formulary inertia, prescriber continuity, and adherence-driven switching resistance.

Benchmarking framework

Key comparables share:

• oral administration
• established clinical role
• mature IP
• meaningful generic competition

Financial divergence mainly reflects:

• degree of FDC dominance vs component availability
• number of generic competitors
• strength of any remaining lifecycle patents

Key data points investors typically track for TRALEMENT (and what they imply)

Financial driver	What it means for TRALEMENT	Market signal
Net price trend	PBM rebates and pricing pressure	Branded revenue compression even if units hold
Unit share	Generic substitution impact	Persistent share erosion post-entry
Gross to net delta	Contracting changes	Rebate rate increases often accompany generic threats
Pharmacy channel inventory	Reorders and stocking	Faster reorder slowdown accelerates decline
SKU-specific competition	Packaging and strength-level generics	Temporary stabilization if gaps exist, then re-erosion
Litigation/Orange Book events	Entry timing or authorized generics	One-time step changes in volume and price

Key Takeaways

• TRALEMENT’s revenue trajectory is shaped primarily by mature hypertension market mechanics: generic substitution, payer tiering, and component dosing alternatives.
• Fixed-dose combination value (adherence and regimen simplification) supports residual demand but generally cannot offset cost-driven switching once generics dominate.
• Financial sensitivity centers on net pricing (rebates and PBM contracting) and unit share loss rather than on clinical adoption.
• Any remaining patent or Orange Book constraints matter mostly for timing of incremental generic entrants, not for reversing long-run brand erosion in a mature small-molecule category.

FAQs

1. Does TRALEMENT have an authorized generic risk after Orange Book resolution?
2. Which US states allow pharmacy substitution for TRALEMENT if an AB-rated generic exists?
3. How do prior authorization and step therapy policies typically affect TRALEMENT branded volume?
4. What happens to branded hypertension FDC sales when the number of generic ANDAs increases?
5. How do supply stability and manufacturing constraints of generics impact TRALEMENT’s remaining net sales?

References

No sources were provided in the prompt to cite.

DrugChatter Q&A for TRALEMENT

Does medicare cover tralement?